MedinCell (0ACH)
London Stock Exchange · UK · prices in EUR · close of 27 Oct 2026
Key indicators
| Last close | EUR 26.43 |
|---|---|
| 52-week range | 19.69 – 39.38 |
| Return, 1 month / 3 months | +14.1% / −0.3% |
| Return, 1 year / 3 years | −27.3% / +347.2% |
| Trend | Uptrend |
| RSI (14) | 55 |
| Volatility (1 year) | 53.9% |
| Worst drawdown (1 year) | -45.4% |
| Average daily value traded | 0.07M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
MedinCell is a pharmaceutical company based in France that develops long-acting injectable medicines. Its technology forms tiny deposits in the body that release a drug steadily over time, which can help patients take their treatment less often. The company works with pharmaceutical partners to develop these products and to bring them through clinical testing and to market. Its work covers several therapeutic areas, including treatments for serious and chronic conditions.
MedinCell trades under the code 0ACH on the London Stock Exchange in UK, with its price quoted in euros (EUR). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
MedinCell (0ACH) trades on the London Stock Exchange in UK. It last closed at EUR 26.43 on 27 October 2026.
Its price-based Market X-Ray is 36 out of 100 (a weak price profile), ranking 2,818 of 3,788 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 27.3% and over the last three months it fell 0.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 45 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | 6.5% | ||
| From 52-week high | -31.0% | ||
| Momentum | 45 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -0.3% | ||
| 6-month return | 12.5% | ||
| 12-month return, skipping the last month | -36.3% | ||
| Stability (higher is calmer) | 24 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 53.9% | ||
| Worst drawdown, 1 year (smaller is calmer) | -45.4% | ||
| Liquidity | 27 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.07M EUR | ||
| Zero-volume days | 1.7% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −2.0% |
|---|---|
| 1 month | +14.1% |
| 3 months | −0.3% |
| 6 months | +12.5% |
| 1 year | −27.3% |
| 3 years | +347.2% |
| 5 years | – |
Signals
| 50-day / 200-day average | 24.24 / 24.81 |
|---|---|
| Golden / death cross (60 days) | Death, 32 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.22 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.